INGN 241

Drug Profile

INGN 241

Alternative Names: Ad-mda7; Adenoviral-mda7 - Introgen; Mda 7 gene therapy - Introgen

Latest Information Update: 05 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Columbia University
  • Developer Introgen Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 05 Nov 2009 Discontinued - Phase-I/II for Solid tumours in USA (Intratumoural)
  • 05 Nov 2009 Discontinued - Phase-II for Malignant melanoma in USA (Intratumoural)
  • 05 Nov 2009 Discontinued - Phase-III for Head and neck cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top